Three years ago I stood up in front of a ministry and academic audience in Abuja and made a set of claims about what artificial intelligence was about to do to Nigerian healthcare. The talk was framed around medical tourism — the assumption being that AI would close the gap between domestic care and the international hospitals Nigerians were flying to. Some of those claims have aged well. Others have not. This is the honest report card, and the part where Kinedic puts the next bet down.
What the 2023 thesis got right
The first claim was that diagnostic AI would mature faster than diagnostic infrastructure in Nigeria. That has happened, and the gap is now wider than the talk anticipated. Imaging-AI products that read CT, MRI, mammography, and chest X-ray are now FDA- or CE-cleared at production scale — Aidoc, Annalise.ai, viz.ai, Lunit, Qure.ai — and several of these companies are quietly piloting in West African private hospitals. Med-PaLM 2 and similar clinical large language models hit credible exam-level performance on medical reasoning in 2024. None of this required the local diagnostic base to catch up first. The software arrived.
The second claim was that telemedicine would reshape access for urban Nigerian patients before it touched the rural population. That is now obviously true, and it followed an unflattering pattern. Lagos and Abuja got telehealth platforms (Reliance HMO, Helium Health, Mobihealth, 54gene-adjacent ventures). Rural primary care got the same broken referral chain it had in 2020. The technology adoption tracked household income and Tier-1 city infrastructure, not clinical need.
The third claim was that AI-driven public-health surveillance — wastewater analysis, syndromic surveillance, mobility data fused with hospital admissions — would meaningfully shorten outbreak detection windows. NCDC's collaborations with academic centres on genomic and signal surveillance during the 2023 diphtheria outbreak and the 2024 Lassa season vindicated that prediction. The detection windows shortened. Whether response systems matched the new detection cadence is a separate question.
What the 2023 thesis got wrong, or was too kind to
The talk gave too much weight to AI in drug discovery as a near-term lever for Nigerian patients. Three years on, drug discovery has accelerated globally — but the supply chain into Nigerian pharmacies has not. Currency depreciation against the dollar, persistent naira-USD spreads, and the exit of GSK and Sanofi from local manufacture in 2023–2024 left the Nigerian pharmaceutical market more dependent on imports than it was when the talk was written. AI-discovered molecules will be expensive imports for the foreseeable future. The bottleneck is procurement and reimbursement, not science.
The talk also underestimated how much of the AI value would land first in administration rather than diagnosis. The hospitals that have meaningfully changed their operations with software in the last three years did it through revenue-cycle automation, scheduling, claims processing, and ambient clinical documentation — not through imaging AI. Tier-1 Nigerian hospitals that adopted electronic medical records seriously between 2023 and 2026 (often pushed by HMO requirements) recovered material capacity that was previously absorbed by paperwork. Less glamorous than CT-reading AI. More commercially decisive.
The third miss was the regulatory delay. The talk assumed a Ministry-led national AI-in-health framework would emerge inside three years. NITDA published its national AI strategy. NCAIR ran early pilots. But there is still no specific regulatory pathway in Nigeria for clinical-decision-support software the way the FDA's Software as a Medical Device guidance maps in the US. Hospitals that want to deploy clearance-grade AI today end up building their own internal validation protocols and trusting overseas regulatory equivalence. That is a workable bridge, but it is a bridge, not a road.
What Kinedic is building from this thesis
The integrated diagnostic centre at Mabushi — set to open in 2026 — is the operational answer to most of the above. The unit is being designed as the local clinical anchor for three flows: Kinedic concierge and corporate patients, executive screening cohorts, and rapid-turnaround referrals from selected partner clinics in the federal capital.
The diagnostic AI layer is deliberately conservative. Imaging AI for chest, abdominal, and musculoskeletal CT and MRI — vendor-cleared, evaluated against our own panel before clinical use, reviewed by a human radiologist before report finalisation. Laboratory AI is limited to anomaly detection on result series — not interpretation. This is not a research environment. It is a production diagnostic centre where the cost of a wrong AI-augmented call is a real Nigerian patient, often a senior one, who chose us over flying out.
The harder bet is on the operational layer. Records, scheduling, partner-clinic requisitions, executive-cohort logistics — all of that runs on software designed for the realities of an Abuja operation, not imported from a different healthcare system. Resilience to power and bandwidth interruptions is treated as a clinical requirement, not an inconvenience.
What we expect in the next three years
Diagnostic AI clearance in Nigeria will get a regulatory pathway by 2028, probably co-developed by NAFDAC and NITDA, probably with MDCN providing the clinical-governance layer. Whichever institution leads, the outcome is the same — the bridge becomes a road. Hospitals that built validation discipline early will move faster when that happens. The ones that waited will spend the back half of the decade catching up to their own AI procurement decisions.
Diaspora-driven demand for trusted local care will keep rising. The Nigerian middle and upper class abroad is now large enough, financially mature enough, and concerned enough about parents at home that a domestic concierge medical model is structurally viable for the first time. Kinedic Diaspora is built for that audience.
Domestic medical tourism — Nigerians from Lagos, Kano, and Port Harcourt travelling to Abuja for executive medicine and diagnostics — will become commercially material before international medical tourism into Nigeria does. The political and corporate concentration in the federal capital, combined with a credible diagnostic centre, makes Abuja the natural hub.
AI-augmented executive medicine will be the wedge that proves out clinical AI for the Nigerian private market. High-resource patients tolerate experimentation, are accustomed to second opinions, and provide enough information density per visit for AI tools to add measurable value. The patterns that work in executive medicine will then translate downmarket.
Closing
Some of what I said three years ago was right. Some was overconfident. The honest answer was always going to be a mixed score — the interesting question was never whether AI would arrive, but whether it would arrive into infrastructure that could use it. Kinedic exists to be one of the places where it can.
If you are a hospital, a ministry, an academic partner, or a strategic investor thinking about diagnostic infrastructure in the federal capital, the diagnostic centre at Mabushi is open to conversation. Start one with us.